Southwest Hematology Oncology Conference: Precision Guided Therapy

Phoenix, AZ US
August 10, 2024

The Southwest Hematology Oncology Conference: Precision Guided Therapy is a 1-day educational and scientific meeting that will focus on the updates in the biomarker-guided management of patients with common malignancies. This conference will feature experts discussing the latest diagnostic, therapeutic, and supportive care strategies in cancer management. In addition, expert faculty will place key abstract findings from the 2024 ASCO Annual Meeting into a clinical context and discuss how the results may change the current standards of care. The goals of this conference are to review and critically assess practice-changing results of practice-changing clinical data and expert recommendations to incorporate biomarker-guided therapy in the management of patients with cancer.

Target Audience

  • Hematologists/Medical oncologists
  • Primary care providers
  • Resident/fellows
  • NPs/PAs
  • Pharmacists
  • Oncology Nurses

ORGANIZING COMMITTEE: 

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chairs:

 Sumit Madan, MD - Banner MD Anderson

 Tibor Kovacsovics, MD - City of Hope Phoenix

Learning Objectives

  • Discuss the current and evolving paradigms in precision oncology, across various specialty areas and malignancies.
  • Describe the different testing methodologies available to guide targeted therapies and their appropriate timing.
  • Explain the concept of “tumor agnostic” therapeutics and identify opportunities to optimize treatment planning and side effect management in different malignancies.
  • Discuss how to foster a multi-disciplinary approach to care, collaboration among providers, and how to increase knowledge of and participation in clinical trials.
Course summary
Available credit: 
  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
Course opens: 
05/20/2024
Course expires: 
08/10/2025
Event starts: 
08/10/2024 - 8:00am PDT
Event ends: 
08/10/2024 - 4:52pm PDT
Cost:
$350.00

August 10th, 2024

All times are listed in Mountain Time (MT)

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:25 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:25 AM – 09:30 AM  Session 1 - Hematologic Malignancies

Session Chair: Sumit Madan, MD

08:25 AM – 08:40 AM  Promises of Personalized Medicine: Exploring the Genetic Landscape in Myeloma - Jonathan Keats, PhD

08:40 AM – 08:55 AM  Upfront Treatment of High-Risk Myeloma - Jeremy T. Larsen, MD

08:55 AM – 09:10 AM  CAR-T vs Bispecifics: How to Sequence Immunotherapies - Saurabh Chhabra, MBBS

09:10 AM – 09:20 AM  Thinking Beyond Daratumumab and Cybord in AL Amyloidosis - Tibor Kovacsovics, MD

09:20 AM – 09:30 AM  Discussion


09:30 AM – 10:00 AM  Break & Exhibits


10:00 AM – 11:00 AM  Session 2: Myeloid Malignancies

Session Chair: Tibor Kovacsovics, MD

10:00 AM – 10:15 AM  Management of AML - Focus on Disease and Patient Factors

10:15 AM – 10:30 AM  Updates in the Management of CML

10:30 AM – 10:45 AM  Initiating and Sequencing  Treatments of  Primary Myelofibrosis in 2024

10:45 AM – 11:00 AM  Discussion


11:00 AM – 12:00 PM  Session 3: Lymphoid Malignancies

Session Chair: Matthew Ulrickson, MD

11:00 AM – 11:15 AM Management of newly diagnosed lymphomas in the era of novel therapies 

11:15 AM – 11:30 AM Novel therapies in relapsed NHLs - Javier L. Munoz, MD, MBA

11:30 AM – 12:00 PM Discussion


12:00 PM – 01:00 PM  Lunch & Exhibits

12:15 PM to 1:00 PM

Product Theater Sponsored by Merck in Borein AB

Topic: A Treatment Option for Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

Speaker:

This is a non-CME activity


01:00 PM – 02:00 PM  Session 4: Thoracic Oncology

Session Chair: Jiaxin Niu, MD

01:00 PM – 01:15 PM  Advances in Precision-Guided Therapy in NSCLC - Saba Radhi, MD

01:15 PM – 01:30 PM  Immunotherapy in Lung Cancer: Current and Evolving Strategies - Vamsee Torri, MD

01:30 PM – 02:00 PM  Case-Based Discussion 


02:00 PM – 03:00 PM  Session 5: General Oncology

Session Chair: Chad Cherington, MD

02:00 PM – 02:15 PM  GI Oncology: Updates in Precision-Guided Therapy - Tanios S. Bekaii-Saab, MD

02:15 PM – 02:30 PM  Precision-Guided Approach in Managing GU Malignancies - Jason Brown, MD, PhD

02:30 PM – 02:45 PM  Precision-Guided Therapy in Sarcoma - Mahesh Seetharam, MD, FACP, MBBS

02:45 PM – 03:00 PM  Discussion 


03:00 PM – 03:15 PM  Break & Exhibits


03:15 PM – 04:15 PM  Session 6 - Breast Cancer

Session Chair: Qing Zhao, MD

03:15 PM – 03:30 PM  Molecular-Guided Therapy in Breast Cancer

03:30 PM – 04:15 PM  Discussion - Karen S. Anderson, MD, PhD


04:15 PM  Adjourn

Hyatt Regency Phoenix
122 N 2nd St,
Phoenix, AZ 85004
United States
+1 (602) 252-1234

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chair(s)

Tibor Kovacsovics, MD

has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Other) with Rigel;.
has a financial relationship (Grant Or Contract) with Syndax;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Glycomimetics;.
has a financial relationship (Other) with Servier;.
Session Chair(s)

Qing Zhao

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

jeremy larsen

has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Janssen Oncology;.

Available Credit

  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.